$KRYS

Krystal Biotech Inc

$KRYS

Krystal Biotech Inc

Past 12mo:4mentions2voices

All voices2 calls since Aug 2025show all

Loading price chart…

Recent calls

2 calls

@adamfeuersteinAug 22, 2025 · 10:39 AM

@bio_clouseau This is what $KRYS sent me in response to my question about the study shutdown: “We are continuously reviewing resource allocation across our pipeline to maximize investment in programs with the greatest potential impact and clearest path to approval. The regulatory landscape is a key consideration in this process. Accordingly, the decision to close enrollment in KB707-01 was driven in part by heightened uncertainty regarding potential accelerated approval pathways for intratumoral therapies targeting cutaneous cancers.” This is what $KRYS sent to participating investigators: “We would like to inform you of an important update regarding the KB707-01 clinical study: A recent decision by the regulatory agency has signaled a shift in their approach to drug approvals. Following extensive internal discussions and careful consideration of this evolving landscape, Krystal Biotech, Inc. has made the difficult decision to close future enrollment to the KB707-01 study.”

Open on X

@adamfeuersteinAug 21, 2025 · 12:19 PM

New from me: FDA ‘uncertainty’ forces Krystal Biotech $KRYS to shutter cancer drug trial The decision follows rejection of a similar drug developed by Replimune Group $REPL https://t.co/nY1w3BdmCd

Open on X

About this stock

$KRYS has generated 4 mentions from 2 distinct FinTwit voices over the past 12 months, with the first mention appearing on 2025-08-21. Adam Feuerstein (@adamfeuerstein) accounts for 3 of these mentions, making him the most-active voice discussing the company. The biotech category dominates discussion of this ticker. Feuerstein's coverage focused on a significant development in August 2025 regarding a clinical study closure, with the company citing regulatory uncertainty around accelerated approval pathways for intratumoral therapies targeting cutaneous cancers.

AI-generated from tracked posts · updated Jul 2, 2026